China Shineway Pharmaceutical Group (HKSE:02877) Debt-to-Revenue : 0.07 (As of Dec. 2023)

China Shineway Pharmaceutical Group Debt-to-Revenue Chart

China Shineway Pharmaceutical Group Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Debt-to-Revenue		Get a 7-Day Free Trial					0.15	0.15	0.01	-	0.07

China Shineway Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															-	-	-	0.06	0.07

Competitive Comparison of China Shineway Pharmaceutical Group's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Shineway Pharmaceutical Group's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where China Shineway Pharmaceutical Group's Debt-to-Revenue falls into.

China Shineway Pharmaceutical Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

China Shineway Pharmaceutical Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

China Shineway Pharmaceutical Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

China Shineway Pharmaceutical Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Shineway Pharmaceutical Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

China Shineway Pharmaceutical Group (HKSE:02877) Business Description